NCT04711330View on ClinicalTrials.gov

Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy

Active, not recruitingOBSERVATIONAL
Enrollment

126

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

October 1, 2025

Study Completion Date

October 2, 2025

Conditions
Non Small Cell Lung Cancer Stage IIIImmunotherapy
Trial Locations (6)

3500

Kristof Cuppens, Hasselt

B-9300

Piet Verkouteren, Aalst

B8800

Ingel Demedts, Roeselare

B2300

Lynn Decoster, Turnhout

1066CX

Netherlands Cancer Institute, Amsterdam

2333ZA

Leiden University Medical center, Leiden

All Listed Sponsors
collaborator

The Netherlands Cancer Institute

OTHER

collaborator

Jessa Hospital

OTHER

lead

Leiden University Medical Center

OTHER